Arcellx's Anito-Cel: Compelling Opportunity As Potential Best-In-Class CAR-T Therapy For Multiple Myeloma
- Arcellx leverages proprietary platforms like D-Domain, ddCAR, and ARC-SparX to enhance immune response, targeting multiple myeloma, AML, MDS, and solid tumors. ACLX's lead therapy, anito-cel, shows strong clinical results in relapsed/refractory multiple myeloma, even for high-risk patients. Arcellx's strategic partnership with Kite Pharma validates its technology, potentially leading to milestone payments of up to $935 million.
- 09/10/2024
|
Arcellx, Inc. (ACLX) Reports Q2 Loss, Misses Revenue Estimates
- Arcellx, Inc. (ACLX) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to loss of $0.50 per share a year ago.
- 08/08/2024
|
FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals
- The biotech industry has fallen on hard times over the last few years, no thanks to venture capital drying up, tighter regulatory conditions and the harsh reality of the post-pandemic healthcare environment. As a result, biotech breakthrough stocks fell out of favor with investors and were among the worst performers in the stock market.
- 07/04/2024
|
Arcellx's Strategic Moves With Anito-Cel Aim To Disrupt Myeloma Market
- Arcellx is advancing Anito-cel in a pivotal Phase 2 trial for relapsed or refractory multiple myeloma, showing promising early results. Anito-cel has demonstrated a 100% overall response rate and a 76% complete response rate in early trials. The collaboration with Kite enhances Arcellx's operational capabilities and financial stability, supporting the development of Anito-cel.
- 06/26/2024
|
7 Biotech Stocks to Put on Your Breakthrough Radar
- For those seeking to decipher best speculative opportunities in the market, biotech stocks with breakthrough potential may offer plenty of firepower. Let's get some of the bad stuff out of the way first.
- 05/27/2024
|
Arcellx, Inc. (ACLX) Reports Q1 Loss, Tops Revenue Estimates
- Arcellx, Inc. (ACLX) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to loss of $0.58 per share a year ago.
- 05/09/2024
|
Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
- REDWOOD CITY, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX) and Kite, a Gilead Company (NASDAQ: GILD), today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx's novel and compact D-Domain binder. The companies shared the design of a global, Phase 3 randomized controlled clinical trial, iMMagine-3,.
- 05/09/2024
|
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
- REDWOOD CITY, Calif. & SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX) today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx's novel and compact D-Domain binder. The companies shared the design of a global, Phase 3 randomized controlled clinical trial, iMMagine-3,.
- 05/09/2024
|
Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine
- Biotech breakthrough stocks, along with the sector overall, faced significant challenges over the past two years, with venture capital drying up, shifts in the post-pandemic healthcare landscape and tighter regulatory conditions squeezing already-thin margins. However, 2024 may herald a resurgence for biotech stocks, spurred by an FDA approval spree throughout 2023.
- 05/09/2024
|
Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference
- REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, at 12:45 p.m. ET. A live webcast of this discussion will be accessible from Arcellx's website at www.arcellx.com in the Inv.
- 04/04/2024
|
How Arcellx (ACLX) Stock Stands Out in a Strong Industry
- Arcellx (ACLX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
- 04/04/2024
|
Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
- REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference on Tuesday, March 26, at 1:00 p.m. ET. A live webcast of this discussion will be accessible from Arcellx's website at www.arcellx.com in t.
- 03/20/2024
|
Arcellx to Participate at the TD Cowen 44th Annual Health Care Conference
- REDWOOD CITY, Calif. , Feb. 29, 2024 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the TD Cowen 44th Annual Health Care Conference on Wednesday, March 6, at 2:50 p.m.
- 02/29/2024
|
Arcellx, Inc. (ACLX) Q4 Earnings and Revenues Surpass Estimates
- Arcellx, Inc. (ACLX) came out with quarterly earnings of $0.42 per share, beating the Zacks Consensus Estimate of a loss of $0.63 per share. This compares to loss of $0.76 per share a year ago.
- 02/28/2024
|
Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights
- -- Expanded strategic partnership with Kite -- -- Presented continued robust long-term responses from Phase 1 expansion trial of anito-cel (formerly CART-ddBCMA) in patients with relapsed or refractory multiple myeloma -- -- Ended the quarter with $729.2M, extending cash runway into 2027 -- REDWOOD CITY, Calif. , Feb. 28, 2024 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the fourth quarter and year ended December 31, 2023.
- 02/28/2024
|
The 3 Biotech Stocks That Could Make Your February Unforgettable
- Following a hot year of M&A with biotech stocks, we'll see more of the same in 2024 as drug makers look to build their pipelines ahead of a massive patent cliff. Between now and 2028, pharmaceutical giants stand to lose billions in revenue as blockbuster drug patents expire.
- 02/15/2024
|
Arcellx: Navigating The CAR T-Cell Revolution
- Arcellx: Navigating The CAR T-Cell Revolution
- 01/30/2024
|
Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market
- Biotech stocks, and the sector in general, saw a widespread beat down over the past two years. Venture capital dried up, post-pandemic healthcare landscapes shifted, and regulatory clampdowns tightened already-slim margins.
- 01/16/2024
|
Pharma's Frontline: 3 Stocks Driving Revolutionary Drug Development
- The pharma stock leaders can at times seem overly risk averse with their approach to developing new medicines and cures. With the difficulty of clinical trials and the uncertainty of Federal Drug Administration (FDA) approval, many pharma companies prefer to play it safe rather than bet big.
- 12/15/2023
|
Arcellx Announces Continued Robust Long-Term Responses from Its CART-ddBCMA (anito-cel) Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at ASH
- -- Median duration of response, progression free survival, and overall survival rate not reached with median follow-up after CART-ddBCMA (anito-cel) infusion of 26.5 months – -- The estimated median progression free survival by Kaplan-Meier is 28 months -- -- Oral presentation at ASH will be on Monday, December 11, 2023 at 5 p.m. PT -- -- Company to host a live webcast event with an expert panel of clinicians on Monday, December 11 at 8 p.m.
- 12/08/2023
|
3 Biotech Stocks That Could Be Multibaggers in the Making
- In the dynamic realm of modern medicine, biotech stocks have effectively emerged at the forefront of a transformation. These innovative players are steering us towards a new era of medical marvels with precision and personalization.
- 11/30/2023
|
Arcellx (ACLX) Up 5% on Partnership Expansion With Gilead
- Arcellx (ACLX) and Gilead (GILD) expand their existing collaboration in cancer treatment. This deal is expected to close by year-end.
- 11/16/2023
|
Arcellx: A Strong Contender In The CAR-T Multiple Myeloma Market
- Arcellx's CART-ddBCMA reported strong and competitive data in late-line multiple myeloma patients, positioning it well against CAR-T leader Carvykti. The updated data at ASH show that the efficacy held up and even slightly improved compared to the previous update, and good safety. The partnership with Gilead Sciences provides a cash infusion and de-risks CART-ddBCMA's manufacturing process.
- 11/15/2023
|
Arcellx stock climbs on Gilead investment
- Arcellx Inc (NASDAQ:ACLX) shares jumped 8% to $51.28 in early Wednesday trading after the clinical-stage biotechnology company announced that it has received a $200 million equity investment from Gilead Sciences Inc's Kite as part of an expanded collaboration. Gilead will buy 3.24 million shares of Arcellx at a price of $61.68 per share, representing a 30% premium to Tuesday's closing price.
- 11/15/2023
|
Arcellx's stock set to surge after Gilead makes $200 million investment at a 30% premium
- Shares of Arcellx Inc. ACLX, +4.33% were set to surge Wednesday, after biotechnology company announced a $200 million equity investment by Gilead Sciences Inc.'s GILD, -0.28% Kite as part of an expanded collaboration. Under terms of the investment, Gilead will buy 3.24 million Arcellx shares for $200 million, which will give Gilead a 13% stake in Arcellx, and extend Arcellx's cash runway into 2027.
- 11/15/2023
|
Is a Surprise Coming for Arcellx (ACLX) This Earnings Season?
- Arcellx (ACLX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 11/09/2023
|
4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates
- Let us look at a few biotech companies, ACLX, LEGN, GRCL and EYEN, which are poised to beat third-quarter earnings estimates.
- 11/09/2023
|
Are Medical Stocks Lagging Arcellx (ACLX) This Year?
- Here is how Arcellx, Inc. (ACLX) and Ardelyx (ARDX) have performed compared to their sector so far this year.
- 11/02/2023
|
7 Biotech Stocks to Get In Now Before Investors Catch On
- Biotechnology is the source of some of our strongest and growing revolutions. Gene technology allows us to cure incurable diseases and make miracles happen with living organisms.
- 10/23/2023
|
Is Arcellx (ACLX) Stock Outpacing Its Medical Peers This Year?
- Here is how Arcellx, Inc. (ACLX) and BellRing Brands (BRBR) have performed compared to their sector so far this year.
- 10/17/2023
|
Cancer Drug Approval? 3 Biotech Stocks on the Brink of Breakthroughs
- Autologous chimeric antigen receptor T cell therapy is 0ne of the most promising, relatively new types of cancer treatments. CAR T involves “reprogramming” patients' T cells, which fight hostile cells within the body.
- 10/02/2023
|
Wall Street Analysts Believe Arcellx, Inc. (ACLX) Could Rally 35.56%: Here's is How to Trade
- The average of price targets set by Wall Street analysts indicates a potential upside of 35.6% in Arcellx, Inc. (ACLX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 09/04/2023
|
Arcellx (ACLX) Down on Hold for Lead Program CART-ddBCMA
- Arcellx's (ACLX) study on lead program CART-ddBCMA for treating adult patients with relapsed or refractory multiple myeloma has been put on hold by the FDA. The company's shares decline on the same.
- 06/21/2023
|
Arcellx price target slashed, stock takes a hit as FDA puts hold on clinical trial following patient death
- Analysts at Baird say they still like the long-term outlook for biotechnology company Arcellx Inc (NASDAQ:ACLX) after a clinical trial for its investigational new drug CART-ddBCMA for relapsed or refractory multiple myeloma was put on hold by the US Food and Drug Administration (FDA) following a patient's death. The analysts said they expected the negative regulatory update from Arcellx on Monday night to weigh on the stock, which closed down 7.2% at US$33.23 on Tuesday.
- 06/20/2023
|
Arcellx, Inc. (ACLX) Reports Q1 Loss, Misses Revenue Estimates
- Arcellx, Inc. (ACLX) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of $2.52. This compares to loss of $1.56 per share a year ago.
- 05/08/2023
|
5 Stocks With Recent Price Strength That Still Have Upside
- Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are META, CMG, ACLX, HROW and PRG.
- 05/03/2023
|
Arcellx, Inc. (ACLX) is a Great Momentum Stock: Should You Buy?
- Does Arcellx, Inc. (ACLX) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 04/25/2023
|
Arcellx, Inc. (ACLX) Upgraded to Strong Buy: Here's What You Should Know
- Arcellx, Inc. (ACLX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
- 04/21/2023
|
New Strong Buy Stocks for April 21st
- WOR, RYI, ANVS, ACLX and SIEGY have been added to the Zacks Rank #1 (Strong Buy) List on April 21, 2023.
- 04/21/2023
|
New Strong Buy Stocks for April 17th
- IOT, PNTG, ACLX, ELUXY and AB have been added to the Zacks Rank #1 (Strong Buy) List on April 17, 2023.
- 04/17/2023
|
Best Momentum Stocks to Buy for April 11th
- ACLX, MT and X made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on April 11, 2023.
- 04/11/2023
|
New Strong Buy Stocks for April 11th
- AGESY, ACLX, MT, X and GBX have been added to the Zacks Rank #1 (Strong Buy) List on April 11, 2023.
- 04/11/2023
|
Wall Street Analysts Predict a 29.58% Upside in Arcellx, Inc. (ACLX): Here's What You Should Know
- The average of price targets set by Wall Street analysts indicates a potential upside of 29.6% in Arcellx, Inc. (ACLX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 04/05/2023
|
Earnings Estimates Moving Higher for Arcellx, Inc. (ACLX): Time to Buy?
- Arcellx, Inc. (ACLX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
- 04/04/2023
|
Arcellx, Inc. (ACLX) Reports Q4 Loss, Misses Revenue Estimates
- Arcellx, Inc. (ACLX) delivered earnings and revenue surprises of -7.04% and 100%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 03/29/2023
|
Is a Surprise Coming for Arcellx (ACLX) This Earnings Season?
- Arcellx (ACLX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 03/16/2023
|
Arcellx: The Gilead Deal Derisks And Proves Their Technology
- Arcellx, Inc. produced excellent data for their ddBCMA program. The data helped clinch a deal with Gilead.
- 01/09/2023
|
Arcellx flies on $325M deal with Gilead's Kite for multiple myeloma treatment
- Arcellx shares soared in early trade after the clinical-stage biotechnology company announced a global strategic collaboration with Gilead Sciences' Kite to co-develop and co-commercialize its late-stage product candidate, CART-dddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma. Multiple myeloma is an incurable disease for most patients and the need remains for effective, safe, and broadly accessible therapies.
- 12/09/2022
|
Why Is Arcellx (ACLX) Stock Up 25% Today?
- Investors of Arcellx (NASDAQ: ACLX ) stock are in a great mood today, and the reason is no mystery. Acrellx just disclosed that it's teaming with biopharmaceutical giant Gilead Sciences (NASDAQ: GILD ).
- 12/09/2022
|
Gilead to co-develop Arcellx's multiple myeloma drug
- Gilead Sciences Inc. GILD, +1.91% said Friday that it will co-develop and co-commercialize Arcellx Inc.'s ACLX, +7.22% multiple myeloma treatment candidate, which is currently in Phase 2 clinical trials. Gilead will pay Arcellx $225 million upfront, plus make a $100 million equity investment in the company.
- 12/09/2022
|
These Are the 10 Best-Performing IPOs in 2022 Through October
- The IPO market has been slow this year as investors' risk appetite for new issues hit a record low.
- 11/16/2022
|
Arcellx: Promising Up And Coming Player In The CAR-T Space
- Arcellx shares have risen by 20% since February IPO and are up 131% over the past 3 months. Arcellx's novel synthetic binding scaffold (D-Domain) is designed to overcome limitations of traditional CAR-Ts.
- 08/24/2022
|
Arcellx: The Best Is Yet To Come
- Arcellx produced strong data in a traditional CAR-T product. However, its core USP is its SparX technology.
- 08/23/2022
|
Arcellx Announces Participation at the Barclays Global Healthcare Conference
- FOSTER CITY, Calif., March 10, 2022 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a clinical-stage cell therapy biotechnology company, announced today that chairman and chief executive officer, Rami Elghandour and chief medical officer, Chris Heery, M.D.
- 03/10/2022
|
U.S. IPO Weekly Recap: The February IPO Market Kicks Off With 2 Biotechs
- U.S. IPO Weekly Recap: The February IPO Market Kicks Off With 2 Biotechs
- 02/05/2022
|
CAR-T Player Arcellx Raises $123M Via Initial Public Offering, Opens Trading At $19
- CAR-T company Arcellx Inc ACLX priced its IPO at $15 per share, raising $123.8 million at the low end of the Company's proposed range of $15 - $17. Get the Inside Access Traders Are Using to Profit More and Win Bigger.
- 02/04/2022
|
Arcellx sets IPO terms, looks to raise up to $140.3 million
- Arcellx Inc. ACLX, has set terms for its initial public offering, in which the Maryland-based biotechnology company, which is developing cancer treatments, looks to raise up to $140.25 million. The company said it is offering 8.25 million shares in the IPO, which is expected to price between $15 and $17 a share.
- 01/31/2022
|
